Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
World J Microbiol Biotechnol ; 39(1): 5, 2022 Nov 08.
Article in English | MEDLINE | ID: mdl-36346468

ABSTRACT

Aureocin A53 is an N-formylated antimicrobial peptide (AMP) produced by Staphylococcus aureus. Aureocin A53 has a broad spectrum of antimicrobial activity against human and animal pathogens. In the present study, its antagonistic activity was investigated towards 30 strains of S. aureus and 30 strains of Streptococcus spp. isolated from bovine mastitis cases in Brazil. Bovine mastitis is a disease that causes a major economic impact worldwide. Aureocin A53 inhibited the growth of all 60 strains tested, including multidrug-resistant streptococcal isolates and strains of S. aureus belonging to different pulsotypes. This AMP proved to be bactericidal against the six target strains randomly selected among staphylococci and streptococci, also exhibiting a lytic mode of action against the staphylococcal cells. Furthermore, it was determined that 2,048 AU/mL of the AMP were required to inhibit 99.99% of the cell growth of the strain less sensitive to aureocin A53. Aureocin A53 was not toxic to bovine mammary gland epithelial cells after a 24-h exposure and maintained its antimicrobial activity when tested in the excised-teat model against strains of S. aureus and Streptococcus agalactiae, the species responsible for most intramammary infections, not only in Brazil but in other countries as well. Therefore, the use of aureocin A53 in the development of new pharmacological products for the prophylaxis and/or treatment of bovine mastitis was considered promising.


Subject(s)
Anti-Infective Agents , Mastitis, Bovine , Staphylococcal Infections , Female , Humans , Cattle , Animals , Staphylococcus aureus , Streptococcus agalactiae , Antimicrobial Peptides , Staphylococcal Infections/drug therapy , Staphylococcal Infections/veterinary , Staphylococcus , Anti-Bacterial Agents/pharmacology , Streptococcus , Anti-Infective Agents/pharmacology , Adenosine Monophosphate/pharmacology
2.
J Glob Antimicrob Resist ; 19: 50-52, 2019 12.
Article in English | MEDLINE | ID: mdl-31454564

ABSTRACT

OBJECTIVES: Here we report the draft genome sequence of Staphylococcus agnetis 3682, a strain producing agneticin 3682, a broad-spectrum lantibiotic with potential medical applications. The inhibitory activity of S. agnetis 3682 against multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA) isolates involved in human infections was also investigated. METHODS: A sequencing library was constructed using a Nextera XT DNA Library Preparation Kit. An Illumina MiSeq system was used to perform whole-genome shotgun sequencing. De novo genome assembly was performed using the A5-miseq pipeline. Staphylococcus agnetis 3628 genome annotation was performed by the RAST server, and BAGEL4 and antiSMASH v.4.0 platforms were used for mining bacteriocin gene clusters. The inhibitory activity of S. agnetis 3682 against 20 multidrug-resistant MRSA strains involved in human infections in two Brazilian hospitals was determined by the deferred antagonism assay on brain-heart infusion (BHI) agar plates. RESULTS: The total scaffold size was determined to be 2 502 817bp with a G+C content of 35.6%. Genome analyses revealed 2437 coding sequences, 76 RNA genes, 27 genes involved in drug resistance and 2 bacteriocinogenic gene clusters (for agneticin 3682 and hyicin 4244). Staphylococcus agnetis 3682 inhibited 80% of the MRSA isolates tested. CONCLUSION: This study describes the main features of the draft genome of S. agnetis 3682, a strain producing the first bacteriocin (agneticin 3682) reported in this species. A second gene cluster encoding a sactipeptide was also found in the bacterial chromosome. Agneticin 3682 shows a new potential application against clinical MRSA isolates.


Subject(s)
Bacteriocins/genetics , Bacteriocins/metabolism , Bacteriocins/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcus/genetics , Staphylococcus/metabolism , Anti-Bacterial Agents/pharmacology , Base Composition , Base Sequence , Brazil , Drug Resistance, Multiple, Bacterial/genetics , Genes, Bacterial/genetics , Genome, Bacterial , Humans , Microbial Sensitivity Tests , Multigene Family , Staphylococcal Infections/microbiology , Staphylococcus/isolation & purification
3.
Curr Top Med Chem ; 17(10): 1177-1198, 2017.
Article in English | MEDLINE | ID: mdl-27697045

ABSTRACT

One of the biggest challenges faced presently by clinicians is the emergence of multidrug -resistant pathogens that can infect humans and animals. To control the infections caused by such pathogens the development of new drugs is required. Bacteria are a rich source of ribosomally -synthesized antimicrobial peptides known as bacteriocins, which are characterized by the presence of a self-defense immunity system. Labionin-containing lantibiotics and sactibiotics are posttranslationally modified bacteriocins with peculiar features. Labionin-containing peptides belong to subclass Ic lantibiotics in which the carbacyclic triamino triacid labionin, a structural variant of lanthionine, and a methyl-substitute labionin derivative are found, giving the molecule a labyrinthine structure. Sactibiotics are circular or linear peptides belonging to a distinct bacteriocin class (class V) which is characterized by the presence of cross-linkages formed by the thiol group of cysteine residues and the α-carbon of acceptor amino acids. A few examples of these bacteriocins have been described in the literature to date, although putative gene clusters with the potential to encode such peptides can be found in the genome of many bacterial species. Some peptides already under study exhibit potential biotechnological applications because of their remarkable antibacterial or antiviral activities, as well as their analgesic activity. Therefore, in this review, the main findings concerning these peptides will be addressed and discussed, with an emphasis on their potential use in clinical settings.


Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Antimicrobial Cationic Peptides/chemistry , Antimicrobial Cationic Peptides/pharmacology , Antiviral Agents/pharmacology , Bacteria/drug effects , Viruses/drug effects , Animals , Antiviral Agents/chemistry , Humans , Microbial Sensitivity Tests
4.
Vet Microbiol ; 106(1-2): 61-71, 2005 Mar 20.
Article in English | MEDLINE | ID: mdl-15737474

ABSTRACT

In the present study, 188 coagulase-negative Staphylococcus (CNS) strains were isolated from bovine mastitis cases from 56 different Brazilian dairy herds, located in the Southeast region of the country, and were tested for antimicrobial substance production. Twelve CNS strains (6.4%) exhibited antagonistic activity against a Corynebacterium fimi indicator strain. Most antimicrobial substances were sensitive to proteolytic enzymes suggesting that they might be bacteriocins (Bac). Amongst the CNS producers, six were identified as S. epidermidis, two as S. simulans, two as S. saprophyticus, one as S. hominis and one as S. arlettae. Plasmid profile analysis of these strains revealed the presence of at least one plasmid. The Bac(+) strains presented either no or few antibiotic resistance phenotypes. Three strains were shown to produce a bacteriocin either identical or similar to aureocin A70, a bacteriocin previously isolated from an S. aureus strain isolated from food. The remaining Bac(+) strains produce antimicrobial peptides that seem to be distinct from the best characterised staphylococcal bacteriocins described so far. Some of them were able to inhibit Listeria monocytogenes, an important food-borne pathogen, and several strains of Streptococcus agalactiae associated with bovine mastitis, suggesting a potential use of these bacteriocins either in the prevention or in the treatment of streptococcal mastitis.


Subject(s)
Bacteriocins/biosynthesis , Mastitis, Bovine/microbiology , Staphylococcal Infections/veterinary , Staphylococcus/metabolism , Animals , Anti-Bacterial Agents/pharmacology , Bacteriocins/metabolism , Blotting, Southern/veterinary , Cattle , Coagulase/deficiency , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Drug Resistance, Bacterial , Female , Listeria monocytogenes/growth & development , Microbial Sensitivity Tests/veterinary , Peptide Hydrolases/metabolism , Polymerase Chain Reaction/veterinary , Staphylococcal Infections/metabolism , Staphylococcal Infections/microbiology , Staphylococcus/enzymology , Staphylococcus/genetics , Staphylococcus/growth & development
5.
J Med Microbiol ; 52(Pt 5): 385-387, 2003 May.
Article in English | MEDLINE | ID: mdl-12721313

ABSTRACT

Interpretation of the mupirocin E-test for low-level mupirocin-resistant Staphylococcus aureus strains has been improved by adding the indicator dye tetrazolium. E-tests were compared with agar dilution methods for assessing mupirocin susceptibility. MICs obtained by the agar dilution method and E-tests showed 89.3% agreement within 2 log(2) dilution criteria. The agreement between MICs increased to 100% in the 1 log(2) dilution definition when the indicator dye tetrazolium was added to the E-test. The use of the E-test with tetrazolium reduction is more accurate for determining mupirocin MICs for S. aureus strains.


Subject(s)
Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests/standards , Mupirocin/pharmacology , Staphylococcus aureus/drug effects , Cross Infection/microbiology , Drug Resistance, Bacterial , Humans , Indicators and Reagents/chemistry , Microbial Sensitivity Tests/methods , Nitroblue Tetrazolium/chemistry , Observer Variation , Reproducibility of Results , Staphylococcal Infections/microbiology
6.
Curr Microbiol ; 46(5): 313-7, 2003 May.
Article in English | MEDLINE | ID: mdl-12732956

ABSTRACT

We have characterized the heat-shock response of the nosocomial pathogen Enterococcus faecium. The growth of E. faecium cells was analyzed at different temperatures; little growth was observed at 50 degrees C, and no growth at 52 degrees C or 55 degrees C. In agreement, a marked decrease of general protein synthesis was observed at 52 degrees C, and very light synthesis was detected at 55 degrees C. The heat resistance of E. faecium cells was analyzed by measuring the survival at temperatures higher than 52 degrees C and, after 2 h of incubation, viable cells were still observed at 70 degrees C. By Western blot analysis, two heat-induced proteins were identified as GroEL (65 kDa) and DnaK (75 kDa). Only one isoform for either GroEL or DnaK was found. The gene expression of these heat-shock proteins was also analyzed by pulsed-labeled experiments. The heat-induced proteins showed an increased rate of synthesis during the first 5 min, reaching the highest level of induction after 10 min and returning to the steady-state level after 20 min of heat treatment.


Subject(s)
Cross Infection/microbiology , Enterococcus faecium/growth & development , Escherichia coli Proteins , Heat-Shock Response , Hot Temperature , Chaperonin 60/metabolism , Culture Media , Enterococcus faecium/physiology , Gram-Positive Bacterial Infections/microbiology , HSP70 Heat-Shock Proteins/metabolism , Heat-Shock Proteins/metabolism , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...